2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Hexokinase

Hexokinase

Hexokinase

Related Products

PDF 0.1 MB

Hexokinases (HK) play a central role in cellular glucose metabolism. Hexokinasescatalyse the first obligatory step of glucose metabolism, the ATP-dependent phosphorylation of glucose (Glc) to yield glucose-6-phosphate (Glc-6-P). In addition to maintaining the downhill concentration gradient that permits facilitated glucose entry into cells, this reaction constitutes the first step of all major pathways of glucose utilization, including glycolysis, the pentose phosphate pathway, (PPP) and glycogenesis. As such hexokinases are uniquely positioned to influence the extent and direction of glucose flux within the cell. The PPP represents the principal cellular source of NADPH and plays important roles in redox homeostasis, anabolism and nucleotide synthesis (Rib-5-P, ribulose 5-phosphate). Similarly, glycolysis and glycogenesis play important roles in energy metabolism and storage, respectively. Other important cellular functions, including hexosamine and nucleotide sugar generation for glycosaminoglycan and glycoprotein biosynthesis, also require Glc-6-P as a precursor (UDP-Glc, uridine diphosphate glucose; UDP-GlcNAc, uridine diphosphate N-acetylglucosamine).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13966
    2-Deoxy-D-glucose
    		Inhibitor 99.93%
    2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase.
    2-Deoxy-D-glucose
  • HY-19992
    3-Bromopyruvic acid
    		Inhibitor ≥98.0%
    3-Bromopyruvate (Bromopyruvic acid) is an analogue of pyruvate and a potent hexokinase (HK)-II inhibitor with high tumor selectivity. 3-Bromopyruvate inhibits cell growth and induces apoptosis through interfering with glycolysis. 3-Bromopyruvate induces autophagy by stimulating ROS formation in breast cancer cells. Antimicrobial activities.
    3-Bromopyruvic acid
  • HY-B0486
    Lonidamine
    		Inhibitor 99.73%
    Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis.
    Lonidamine
  • HY-155008
    PROTAC HK2 Degrader-1
    		Degrader 98.66%
    PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine (HY-B0486) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide (HY-14658) as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research.
    PROTAC HK2 Degrader-1
  • HY-134929
    Hexokinase 2 inhibitor 1
    		99.91%
    Hexokinase 2 inhibitor 1 (Compound 2a) is a hexokinase 2 (HK2) inhibitor with anti-tumor activity and can be used in cancer research.
    Hexokinase 2 inhibitor 1
  • HY-13966S
    2-Deoxy-D-glucose-d
    		≥98.0%
    2-Deoxy-D-glucose-d is the deuterium labeled 2-Deoxy-D-glucose. 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase[1][2].
    2-Deoxy-D-glucose-d
  • HY-W000133
    Metrizamide
    		Inhibitor ≥99.0%
    Metrizamide (Amipaque) is used as the contrast medium for angiography in neuroradiological investigations. Metrizamide inhibits human brain hexokinase.
    Metrizamide
  • HY-P10108
    Hexokinase II VDAC binding domain peptide, cell-permeable
    		Inhibitor 98.37%
    Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth.
    Hexokinase II VDAC binding domain peptide, cell-permeable
  • HY-13966S2
    2-Deoxy-D-glucose-13C
    		≥98.0%
    2-Deoxy-D-glucose-13C is the 13C labeled 2-Deoxy-D-glucose. 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase[1][2].
    2-Deoxy-D-glucose-<sup>13</sup>C
  • HY-13966S4
    2-Deoxy-D-glucose-13C-1
    2-Deoxy-D-glucose-13C-1 is the 13C labeled 2-Deoxy-D-glucose. 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase[1][2].
    2-Deoxy-D-glucose-<sup>13</sup>C-1
  • HY-B0486R
    Lonidamine (Standard)
    		Inhibitor
    Lonidamine (Standard) is the analytical standard of Lonidamine. This product is intended for research and analytical applications. Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis.
    Lonidamine (Standard)
Cat. No. Product Name / Synonyms Application Reactivity